{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:54:12Z","timestamp":1772772852963,"version":"3.50.1"},"publisher-location":"Cham","reference-count":108,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031598142","type":"print"},{"value":"9783031598159","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-59815-9_36","type":"book-chapter","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:01:55Z","timestamp":1723154515000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["IL-1 Family Blockade in Cytokine Storm Syndromes"],"prefix":"10.1007","author":[{"given":"Randy Q.","family":"Cron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"10","key":"36_CR1","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1073\/pnas.74.10.4624","volume":"74","author":"CA Dinarello","year":"1977","unstructured":"Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A. 1977;74(10):4624\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"36_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8\u201327.","journal-title":"Immunol Rev"},{"issue":"5","key":"36_CR3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/eji.201141550","volume":"41","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol. 2011;41(5):1203\u201317.","journal-title":"Eur J Immunol"},{"issue":"4","key":"36_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00281-015-0491-7","volume":"37","author":"JB Kuemmerle-Deschner","year":"2015","unstructured":"Kuemmerle-Deschner JB. CAPS \u2013 pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol. 2015;37(4):377\u201385.","journal-title":"Semin Immunopathol"},{"issue":"4","key":"36_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.pcl.2018.04.005","volume":"65","author":"JJY Lee","year":"2018","unstructured":"Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis. Pediatr Clin North Am. 2018;65(4):691\u2013709.","journal-title":"Pediatr Clin North Am"},{"issue":"9","key":"36_CR6","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479\u201386.","journal-title":"J Exp Med"},{"issue":"2","key":"36_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545\u201355.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"36_CR8","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","volume":"66","author":"NT Ilowite","year":"2014","unstructured":"Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66(9):2570\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"36_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"36_CR10","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"key":"36_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1546-0096-12-13","volume":"12","author":"ML Stoll","year":"2014","unstructured":"Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12:13.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"36_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/gene.2012.3","volume":"13","author":"A Ravelli","year":"2012","unstructured":"Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289\u201398.","journal-title":"Genes Immun"},{"issue":"5","key":"36_CR13","first-page":"1133","volume":"34","author":"EM Behrens","year":"2007","unstructured":"Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133\u20138.","journal-title":"J Rheumatol"},{"issue":"3","key":"36_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/art.22416","volume":"56","author":"J Bleesing","year":"2007","unstructured":"Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(3):965\u201371.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"36_CR15","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/art.38793","volume":"66","author":"KM Kaufman","year":"2014","unstructured":"Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66(12):3486\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"36_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","volume":"49","author":"SJ Vastert","year":"2010","unstructured":"Vastert SJ, van Wijk R, D\u2019Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49(3):441\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"36_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11926-014-0439-2","volume":"16","author":"M Zhang","year":"2014","unstructured":"Zhang M, Behrens EM, Atkinson TP, Shakoory B, Grom AA, Cron RQ. Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep. 2014;16(9):439\u201346.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"36_CR18","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.4049\/jimmunol.1501284","volume":"196","author":"M Zhang","year":"2016","unstructured":"Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, et al. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. J Immunol. 2016;196(6):2492\u2013503.","journal-title":"J Immunol"},{"issue":"10","key":"36_CR19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2014-11-610816","volume":"125","author":"WA Spessott","year":"2015","unstructured":"Spessott WA, Sanmillan ML, McCormick ME, Patel N, Villanueva J, Zhang K, et al. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood. 2015;125(10):1566\u201377.","journal-title":"Blood"},{"issue":"6","key":"36_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/art.40438","volume":"70","author":"GS Schulert","year":"2018","unstructured":"Schulert GS, Zhang M, Husami A, Fall N, Brunner H, Zhang K, et al. Brief report: novel UNC13D intronic variant disrupting an NF-kappaB enhancer in a patient with recurrent macrophage activation syndrome and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70(6):963\u201370.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"36_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1084\/jem.20140964","volume":"212","author":"MR Jenkins","year":"2015","unstructured":"Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, et al. Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212(3):307\u201317.","journal-title":"J Exp Med"},{"issue":"10","key":"36_CR22","first-page":"2081","volume":"33","author":"EM Behrens","year":"2006","unstructured":"Behrens EM, Kreiger PA, Cherian S, Cron RQ. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol. 2006;33(10):2081\u20134.","journal-title":"J Rheumatol"},{"issue":"2","key":"36_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2011","unstructured":"Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50(2):417\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"36_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275\u201381.","journal-title":"Crit Care Med"},{"key":"36_CR25","doi-asserted-by":"publisher","first-page":"e28581","DOI":"10.1002\/pbc.28581","volume":"67","author":"S Bami","year":"2020","unstructured":"Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM, et al. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2020;67:e28581.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"36_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326\u201334.","journal-title":"Arthritis Rheumatol"},{"key":"36_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s12185-022-03430-9","volume":"116","author":"L Naymagon","year":"2022","unstructured":"Naymagon L. Anakinra for the treatment of adult secondary HLH: a retrospective experience. Int J Hematol. 2022;116:947\u201355.","journal-title":"Int J Hematol"},{"issue":"12","key":"36_CR28","doi-asserted-by":"publisher","first-page":"e27997","DOI":"10.1002\/pbc.27997","volume":"66","author":"SR Kim","year":"2019","unstructured":"Kim SR, Kissoon-Larkin T, Horn B, Elder M. Anakinra as an agent to control hemophagocytic lymphohistiocytosis in Griscelli type 2. Pediatr Blood Cancer. 2019;66(12):e27997.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"36_CR29","doi-asserted-by":"publisher","first-page":"e28897","DOI":"10.1002\/pbc.28897","volume":"68","author":"A Vagrecha","year":"2021","unstructured":"Vagrecha A, Patel HB, Mamdouhi T, Acharya S, Appiah-Kubi A, Aygun B, et al. Effect of COVID-19 on anakinra-induced remission in homozygous STX11 hemophagocytosis lymphohistiocytosis. Pediatr Blood Cancer. 2021;68(6):e28897.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"36_CR30","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1016\/S2665-9913(20)30335-0","volume":"2","author":"RQ Cron","year":"2020","unstructured":"Cron RQ, Schulert GS, Tattersall RS. Defining the scourge of COVID-19 hyperinflammatory syndrome. Lancet Rheumatol. 2020;2(12):e727\u20139.","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"36_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jama.2021.9508","volume":"326","author":"R Caricchio","year":"2021","unstructured":"Caricchio R, Abbate A, Gordeev I, Meng J, Hsue PY, Neogi T, et al. Effect of Canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA. 2021;326(3):230\u20139.","journal-title":"JAMA"},{"key":"36_CR32","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","volume":"27","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752\u201360.","journal-title":"Nat Med"},{"issue":"10","key":"36_CR33","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41591-021-01500-9","volume":"27","author":"RQ Cron","year":"2021","unstructured":"Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-19. Nat Med. 2021;27(10):1674\u20135.","journal-title":"Nat Med"},{"issue":"1","key":"36_CR34","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S2665-9913(21)00353-2","volume":"4","author":"DA Kelmenson","year":"2022","unstructured":"Kelmenson DA, Cron RQ. Who, what, and when-effective therapy for severe COVID-19. Lancet Rheumatol. 2022;4(1):e2\u20133.","journal-title":"Lancet Rheumatol"},{"key":"36_CR35","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2665-9913(20)30165-X","volume":"2","author":"RQ Cron","year":"2020","unstructured":"Cron RQ. Coronavirus is the trigger but the immune response is deadly. Lancet Rheumatol. 2020;2:e370\u20131.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"36_CR36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3899\/jrheum.200334","volume":"47","author":"RQ Cron","year":"2020","unstructured":"Cron RQ, Chatham WW. The rheumatologist\u2019s role in COVID-19. J Rheumatol. 2020;47(5):639\u201342.","journal-title":"J Rheumatol"},{"issue":"7","key":"36_CR37","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/art.41285","volume":"72","author":"LA Henderson","year":"2020","unstructured":"Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7):1059\u201363.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"36_CR38","first-page":"149","volume":"12","author":"DD Reiff","year":"2022","unstructured":"Reiff DD, Zhang M, Smitherman EA, Mannion ML, Stoll ML, Weiser P, et al. A rare STXBP2 mutation in severe COVID-19 and secondary cytokine storm syndrome. Life (Basel). 2022;12(2):149.","journal-title":"Life (Basel)"},{"issue":"6","key":"36_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/MOP.0000000000001061","volume":"33","author":"GS Schulert","year":"2021","unstructured":"Schulert GS, Blum SA, Cron RQ. Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children. Curr Opin Pediatr. 2021;33(6):549\u201355.","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"36_CR40","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/S2665-9913(22)00068-6","volume":"4","author":"RQ Cron","year":"2022","unstructured":"Cron RQ. No perfect therapy for the imperfect COVID-19 cytokine storm. Lancet Rheumatol. 2022;4(5):e308\u201310.","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"36_CR41","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/S2665-9913(21)00011-4","volume":"3","author":"RQ Cron","year":"2021","unstructured":"Cron RQ. COVID-19 cytokine storm: targeting the appropriate cytokine. Lancet Rheumatol. 2021;3(4):e236\u2013e7.","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"36_CR42","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407\u201318.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"36_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-022-01056-8","volume":"24","author":"DD Reiff","year":"2022","unstructured":"Reiff DD, Cron RQ. Who would have predicted multisystem inflammatory syndrome in children? Curr Rheumatol Rep. 2022;24(1):1\u201311.","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"36_CR44","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/art.42062","volume":"74","author":"LA Henderson","year":"2022","unstructured":"Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 2022;74(4):e1\u2013e20.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"36_CR45","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/acr2.11331","volume":"3","author":"DD Reiff","year":"2021","unstructured":"Reiff DD, Cron RQ. Performance of cytokine storm syndrome scoring systems in pediatric COVID-19 and multisystem inflammatory syndrome in children. ACR Open Rheumatol. 2021;3(12):820\u20136.","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"36_CR46","first-page":"417","volume":"11","author":"A Vagrecha","year":"2022","unstructured":"Vagrecha A, Zhang M, Acharya S, Lozinsky S, Singer A, Levine C, et al. Hemophagocytic Lymphohistiocytosis gene variants in multisystem inflammatory syndrome in children. Biology (Basel). 2022;11(3):417.","journal-title":"Biology (Basel)"},{"key":"36_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2102605","volume":"385","author":"MBF Son","year":"2021","unstructured":"Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. Multisystem inflammatory syndrome in children \u2013 initial therapy and outcomes. N Engl J Med. 2021;385:23\u201334.","journal-title":"N Engl J Med"},{"issue":"8","key":"36_CR48","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137.","journal-title":"Oncologist"},{"issue":"6","key":"36_CR49","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u20138.","journal-title":"Nat Med"},{"issue":"6","key":"36_CR50","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"issue":"3","key":"36_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/diseases10030041","volume":"10","author":"P Ferreros","year":"2022","unstructured":"Ferreros P, Trapero I. Interleukin inhibitors in cytokine release syndrome and neurotoxicity secondary to CAR-T therapy. Diseases. 2022;10(3):41.","journal-title":"Diseases"},{"issue":"6","key":"36_CR52","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/ana.24806","volume":"80","author":"DL Kenney-Jung","year":"2016","unstructured":"Kenney-Jung DL, Vezzani A, Kahoud RJ, LaFrance-Corey RG, Ho ML, Muskardin TW, et al. Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol. 2016;80(6):939\u201345.","journal-title":"Ann Neurol"},{"issue":"12","key":"36_CR53","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/acn3.51229","volume":"7","author":"YC Lai","year":"2020","unstructured":"Lai YC, Muscal E, Wells E, Shukla N, Eschbach K, Hyeong Lee K, et al. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 2020;7(12):2467\u201374.","journal-title":"Ann Clin Transl Neurol"},{"key":"36_CR54","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","volume":"2","author":"P Mehta","year":"2020","unstructured":"Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2:e358\u201367.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"36_CR55","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/acr2.11135","volume":"2","author":"LA Monteagudo","year":"2020","unstructured":"Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. 2020;2(5):276\u201382.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"36_CR56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","volume":"19","author":"O Phadke","year":"2021","unstructured":"Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. 2021;19(1):98.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"12","key":"36_CR57","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1084\/jem.20141091","volume":"211","author":"A Kitamura","year":"2014","unstructured":"Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K. An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med. 2014;211(12):2385\u201396.","journal-title":"J Exp Med"},{"issue":"10","key":"36_CR58","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ng.3066","volume":"46","author":"N Romberg","year":"2014","unstructured":"Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135\u20139.","journal-title":"Nat Genet"},{"issue":"10","key":"36_CR59","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140\u20136.","journal-title":"Nat Genet"},{"issue":"5","key":"36_CR60","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","volume":"139","author":"SW Canna","year":"2017","unstructured":"Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139(5):1698\u2013701.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"36_CR61","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/imr.12616","volume":"281","author":"G Kaplanski","year":"2018","unstructured":"Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. 2018;281(1):138\u201353.","journal-title":"Immunol Rev"},{"issue":"1","key":"36_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","volume":"3","author":"DT Lounder","year":"2019","unstructured":"Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019;3(1):47\u201350.","journal-title":"Blood Adv"},{"key":"36_CR63","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT. Emapalumab: first global approval. Drugs. 2019;79:99\u2013103.","journal-title":"Drugs"},{"issue":"13","key":"36_CR64","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","volume":"131","author":"C Girard-Guyonvarc\u2019h","year":"2018","unstructured":"Girard-Guyonvarc\u2019h C, Palomo J, Martin P, Rodriguez E, Troccaz S, Palmer G, et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood. 2018;131(13):1430\u201341.","journal-title":"Blood"},{"issue":"13","key":"36_CR65","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss ES, Girard-Guyonvarc\u2019h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442\u201355.","journal-title":"Blood"},{"issue":"10","key":"36_CR66","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","volume":"106","author":"K Mazodier","year":"2005","unstructured":"Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, Schleinitz N, et al. Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome. Blood. 2005;106(10):3483\u20139.","journal-title":"Blood"},{"issue":"2","key":"36_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","volume":"160","author":"M Shimizu","year":"2015","unstructured":"Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160(2):277\u201381.","journal-title":"Clin Immunol"},{"issue":"12","key":"36_CR68","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","volume":"78","author":"VE Saper","year":"2019","unstructured":"Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78(12):1722\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"36_CR69","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71(11):1943\u201354.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"36_CR70","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","volume":"81","author":"VE Saper","year":"2022","unstructured":"Saper VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, Prahalad S, Canna S, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2022;81(3):406\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"36_CR71","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.42137","volume":"74","author":"BA Binstadt","year":"2022","unstructured":"Binstadt BA, Nigrovic PA. The conundrum of lung disease and drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74(7):1122\u201331.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"36_CR72","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1136\/annrheumdis-2020-217426","volume":"81","author":"VE Saper","year":"2022","unstructured":"Saper VE, Chen G, Guillerman RP, Khatri P, Cron RQ, Mellins ED. Response to: \u2018successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease\u2019 by Sato et al. Ann Rheum Dis. 2022;81(4):e62.","journal-title":"Ann Rheum Dis"},{"key":"36_CR73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10875-022-01353-y","volume":"43","author":"JE Rood","year":"2022","unstructured":"Rood JE, Rezk A, Pogoriler J, Finn LS, Burnham JM, Josephson MB, et al. Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1beta and IL-18. J Clin Immunol. 2022;43:101\u20138.","journal-title":"J Clin Immunol"},{"issue":"4","key":"36_CR74","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10875-022-01236-2","volume":"42","author":"AV Geerlinks","year":"2022","unstructured":"Geerlinks AV, Dvorak AM, Consortium XDT. A case of XIAP deficiency successfully managed with Tadekinig Alfa (rhIL-18BP). J Clin Immunol. 2022;42(4):901\u20133.","journal-title":"J Clin Immunol"},{"issue":"4","key":"36_CR75","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/blood-2015-07-659813","volume":"127","author":"JE Rood","year":"2016","unstructured":"Rood JE, Rao S, Paessler M, Kreiger PA, Chu N, Stelekati E, et al. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice. Blood. 2016;127(4):426\u201335.","journal-title":"Blood"},{"key":"36_CR76","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3389\/fimmu.2018.02642","volume":"9","author":"JE Rood","year":"2018","unstructured":"Rood JE, Burn TN, Neal V, Chu N, Behrens EM. Disruption of IL-33 signaling limits early CD8+ T cell effector function leading to exhaustion in murine hemophagocytic lymphohistiocytosis. Front Immunol. 2018;9:2642.","journal-title":"Front Immunol"},{"issue":"12","key":"36_CR77","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1016\/S2665-9913(20)30340-4","volume":"2","author":"G Zizzo","year":"2020","unstructured":"Zizzo G, Cohen PL. Imperfect storm: is interleukin-33 the Achilles heel of COVID-19? Lancet Rheumatol. 2020;2(12):e779\u2013e90.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"36_CR78","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","volume":"29","author":"A Ravelli","year":"2015","unstructured":"Ravelli A, Davi S, Minoia F, Martini A, Cron RQ. Macrophage activation syndrome. Hematol Oncol Clin North Am. 2015;29(5):927\u201341.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"36_CR79","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/art.40071","volume":"69","author":"EM Behrens","year":"2017","unstructured":"Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol. 2017;69(6):1135\u201343.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"36_CR80","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/ncprheum0919","volume":"4","author":"A Kelly","year":"2008","unstructured":"Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4(11):615\u201320.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"4","key":"36_CR81","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3899\/jrheum.091046","volume":"37","author":"M Durand","year":"2010","unstructured":"Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010;37(4):879\u201380.","journal-title":"J Rheumatol"},{"issue":"1","key":"36_CR82","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/RHU.0b013e318205092d","volume":"17","author":"N Bruck","year":"2011","unstructured":"Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17(1):23\u20137.","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"36_CR83","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/imj.12002","volume":"42","author":"NK Loh","year":"2012","unstructured":"Loh NK, Lucas M, Fernandez S, Prentice D. Successful treatment of macrophage activation syndrome complicating adult still disease with anakinra. Intern Med J. 2012;42(12):1358\u201362.","journal-title":"Intern Med J"},{"issue":"5","key":"36_CR84","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3899\/jrheum.121098","volume":"40","author":"PJ Kahn","year":"2013","unstructured":"Kahn PJ, Cron RQ. Higher-dose anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol. 2013;40(5):743\u20134.","journal-title":"J Rheumatol"},{"issue":"4","key":"36_CR85","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5152\/TurkPediatriArs.2015.3299","volume":"50","author":"K Barut","year":"2015","unstructured":"Barut K, Yucel G, Sinoplu AB, Sahin S, Adrovic A, Kasapcopur O. Evaluation of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: single center experience over a one-year period. Turk Pediatri Ars. 2015;50(4):206\u201310.","journal-title":"Turk Pediatri Ars"},{"issue":"1","key":"36_CR86","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1086\/685112","volume":"6","author":"MV Mehta","year":"2016","unstructured":"Mehta MV, Manson DK, Horn EM, Haythe J. An atypical presentation of adult-onset Still\u2019s disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature. Pulm Circ. 2016;6(1):136\u201342.","journal-title":"Pulm Circ"},{"issue":"6","key":"36_CR87","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","volume":"45","author":"A Lenert","year":"2016","unstructured":"Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset Still\u2019s disease: a single center case series and comparison with literature. Semin Arthritis Rheum. 2016;45(6):711\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"36_CR88","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00296-016-3545-9","volume":"36","author":"S Aytac","year":"2016","unstructured":"Aytac S, Batu ED, Unal S, Bilginer Y, Cetin M, Tuncer M, et al. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. Rheumatol Int. 2016;36(10):1421\u20139.","journal-title":"Rheumatol Int"},{"key":"36_CR89","first-page":"3717392","volume":"2016","author":"A Kumar","year":"2016","unstructured":"Kumar A, Kato H. Macrophage activation syndrome associated with adult-onset Still\u2019s disease successfully treated with anakinra. Case Rep Rheumatol. 2016;2016:3717392.","journal-title":"Case Rep Rheumatol"},{"key":"36_CR90","doi-asserted-by":"publisher","first-page":"2071815","DOI":"10.1155\/2016\/2071815","volume":"2016","author":"A Agnihotri","year":"2016","unstructured":"Agnihotri A, Ruff A, Gotterer L, Walker A, McKenney AH, Brateanu A. Adult onset Still\u2019s disease associated with mycoplasma pneumoniae infection and hemophagocytic lymphohistiocytosis. Case Rep Med. 2016;2016:2071815.","journal-title":"Case Rep Med"},{"key":"36_CR91","first-page":"8605274","volume":"2016","author":"EJ Schafer","year":"2016","unstructured":"Schafer EJ, Jung W, Korsten P. Combination immunosuppressive therapy including rituximab for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adult-onset Still\u2019s disease. Case Rep Rheumatol. 2016;2016:8605274.","journal-title":"Case Rep Rheumatol"},{"issue":"24","key":"36_CR92","doi-asserted-by":"publisher","first-page":"e6656","DOI":"10.1097\/MD.0000000000006656","volume":"96","author":"F Parisi","year":"2017","unstructured":"Parisi F, Paglionico A, Varriano V, Ferraccioli G, Gremese E. Refractory adult-onset still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8 mg\/kg\/d) of anakinra. Medicine (Baltimore). 2017;96(24):e6656.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"36_CR93","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","volume":"37","author":"HE Sonmez","year":"2018","unstructured":"Sonmez HE, Demir S, Bilginer Y, Ozen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018;37(12):3329\u201335.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"36_CR94","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/03009742.2013.863968","volume":"43","author":"V Lilleby","year":"2014","unstructured":"Lilleby V, Haydon J, Sanner H, Krossness BK, Ringstad G, Flato B. Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis. Scand J Rheumatol. 2014;43(2):171\u20133.","journal-title":"Scand J Rheumatol"},{"key":"36_CR95","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1546-0096-12-26","volume":"12","author":"A Shafferman","year":"2014","unstructured":"Shafferman A, Birmingham JD, Cron RQ. High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J. 2014;12:26.","journal-title":"Pediatr Rheumatol Online J"},{"key":"36_CR96","first-page":"953","volume":"34","author":"RQ Cron","year":"2016","unstructured":"Cron RQ, Chatham WW. Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes. Clin Exp Rheumatol. 2016;34:953.","journal-title":"Clin Exp Rheumatol"},{"key":"36_CR97","doi-asserted-by":"crossref","unstructured":"Tayer-Shifman OE, Ben-Chetrit E. Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome \u2013 successful use of PET- CT and Anakinra in its diagnosis and treatment. Mod Rheumatol. 2015;25:954-7.","DOI":"10.3109\/14397595.2013.844403"},{"issue":"5","key":"36_CR98","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/art.38345","volume":"66","author":"V Mohr","year":"2014","unstructured":"Mohr V, Schulz A, Lohse P, Schumann C, Debatin KM, Schuetz C. Urticaria, fever, and hypofibrinogenemia. Arthritis Rheumatol. 2014;66(5):1377.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"36_CR99","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/acr.22527","volume":"67","author":"GS Schulert","year":"2015","unstructured":"Schulert GS, Bove K, McMasters R, Campbell K, Leslie N, Grom AA. 11-month-old infant with periodic fevers, recurrent liver dysfunction, and perforin gene polymorphism. Arthritis Care Res. 2015;67(8):1173\u20139.","journal-title":"Arthritis Care Res"},{"key":"36_CR100","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3389\/fimmu.2018.02162","volume":"9","author":"J Barsalou","year":"2018","unstructured":"Barsalou J, Blincoe A, Fernandez I, Dal-Soglio D, Marchitto L, Selleri S, et al. Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome. Front Immunol. 2018;9:2162.","journal-title":"Front Immunol"},{"issue":"7","key":"36_CR101","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/INF.0b013e31828df4d1","volume":"32","author":"M Butin","year":"2013","unstructured":"Butin M, Mekki Y, Phan A, Billaud G, Di Filippo S, Javouhey E, et al. Successful immunotherapy in life-threatening parvovirus B19 infection in a child. Pediatr Infect Dis J. 2013;32(7):789\u201392.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"36_CR102","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PCC.0000000000000078","volume":"15","author":"S Rajasekaran","year":"2014","unstructured":"Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med. 2014;15(5):401\u20138.","journal-title":"Pediatr Crit Care Med"},{"issue":"Suppl 1","key":"36_CR103","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12288-013-0299-3","volume":"30","author":"N Kumar","year":"2014","unstructured":"Kumar N, Goyal J, Goel A, Shakoory B, Chatham W. Macrophage activation syndrome secondary to human monocytic ehrlichiosis. Indian J Hematol Blood Transfus. 2014;30(Suppl 1):145\u20137.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"36_CR104","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/rcr2.137","volume":"4","author":"C Divithotawela","year":"2016","unstructured":"Divithotawela C, Garrett P, Westall G, Bhaskar B, Tol M, Chambers DC. Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor \u2013 anakinra. Respirol Case Rep. 2016;4(1):4\u20136.","journal-title":"Respirol Case Rep"},{"key":"36_CR105","doi-asserted-by":"publisher","unstructured":"Wohlfarth P, Agis H, Gualdoni GA, Weber J, Staudinger T, Schellongowski P, et al. Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis. J Intensive Care Med. 2017. https:\/\/doi.org\/10.1177\/0885066617711386.","DOI":"10.1177\/0885066617711386"},{"issue":"7","key":"36_CR106","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s10875-017-0439-x","volume":"37","author":"B Kumar","year":"2017","unstructured":"Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults. J Clin Immunol. 2017;37(7):638\u201343.","journal-title":"J Clin Immunol"},{"key":"36_CR107","doi-asserted-by":"publisher","first-page":"bcr2017221264","DOI":"10.1136\/bcr-2017-221264","volume":"2017","author":"AJ Ocon","year":"2017","unstructured":"Ocon AJ, Bhatt BD, Miller C, Peredo RA. Safe usage of anakinra and dexamethasone to treat refractory hemophagocytic lymphohistiocytosis secondary to acute disseminated histoplasmosis in a patient with HIV\/AIDS. BMJ Case Rep. 2017;2017:bcr2017221264.","journal-title":"BMJ Case Rep"},{"issue":"50","key":"36_CR108","doi-asserted-by":"publisher","first-page":"e9283","DOI":"10.1097\/MD.0000000000009283","volume":"96","author":"C Nusshag","year":"2017","unstructured":"Nusshag C, Morath C, Zeier M, Weigand MA, Merle U, Brenner T. Hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient successfully treated by plasmapheresis: a case report and review of the literature. Medicine (Baltimore). 2017;96(50):e9283.","journal-title":"Medicine (Baltimore)"}],"container-title":["Advances in Experimental Medicine and Biology","Cytokine Storm Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-59815-9_36","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:07:45Z","timestamp":1723154865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-59815-9_36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031598142","9783031598159"],"references-count":108,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-59815-9_36","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"9 August 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}